PortalPublikationenFactors Influencing the Adjuvant Therapy Decision: Results o...

Factors Influencing the Adjuvant Therapy Decision: Results of a Real-World Multicenter Data Analysis of 904 Melanoma Patients

Standard

Factors Influencing the Adjuvant Therapy Decision: Results of a Real-World Multicenter Data Analysis of 904 Melanoma Patients. / Lodde, Georg; Forschner, Andrea; Hassel, Jessica; Wulfken, Lena M; Meier, Friedegund; Mohr, Peter; Kähler, Katharina; Schilling, Bastian; Loquai, Carmen; Berking, Carola; Hüning, Svea; Schatton, Kerstin; Gebhardt, Christoffer; Eckardt, Julia; Gutzmer, Ralf; Reinhardt, Lydia; Glutsch, Valerie; Nikfarjam, Ulrike; Erdmann, Michael; Stang, Andreas; Kowall, Bernd; Roesch, Alexander; Ugurel, Selma; Zimmer, Lisa; Schadendorf, Dirk; Livingstone, Elisabeth.

in: CANCERS, Jahrgang 13, Nr. 10, 2319, 12.05.2021.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Lodde, G, Forschner, A, Hassel, J, Wulfken, LM, Meier, F, Mohr, P, Kähler, K, Schilling, B, Loquai, C, Berking, C, Hüning, S, Schatton, K, Gebhardt, C, Eckardt, J, Gutzmer, R, Reinhardt, L, Glutsch, V, Nikfarjam, U, Erdmann, M, Stang, A, Kowall, B, Roesch, A, Ugurel, S, Zimmer, L, Schadendorf, D & Livingstone, E 2021, 'Factors Influencing the Adjuvant Therapy Decision: Results of a Real-World Multicenter Data Analysis of 904 Melanoma Patients', CANCERS, Jg. 13, Nr. 10, 2319. https://doi.org/10.3390/cancers13102319

APA

Lodde, G., Forschner, A., Hassel, J., Wulfken, L. M., Meier, F., Mohr, P., Kähler, K., Schilling, B., Loquai, C., Berking, C., Hüning, S., Schatton, K., Gebhardt, C., Eckardt, J., Gutzmer, R., Reinhardt, L., Glutsch, V., Nikfarjam, U., Erdmann, M., ... Livingstone, E. (2021). Factors Influencing the Adjuvant Therapy Decision: Results of a Real-World Multicenter Data Analysis of 904 Melanoma Patients. CANCERS, 13(10), [2319]. https://doi.org/10.3390/cancers13102319

Vancouver

Lodde G, Forschner A, Hassel J, Wulfken LM, Meier F, Mohr P et al. Factors Influencing the Adjuvant Therapy Decision: Results of a Real-World Multicenter Data Analysis of 904 Melanoma Patients. CANCERS. 2021 Mai 12;13(10). 2319. https://doi.org/10.3390/cancers13102319

Bibtex

@article{4bced8cab9b1401f94baa8410ce905c1,
title = "Factors Influencing the Adjuvant Therapy Decision: Results of a Real-World Multicenter Data Analysis of 904 Melanoma Patients",
abstract = "Adjuvant treatment of melanoma patients with immune-checkpoint inhibition (ICI) and targeted therapy (TT) significantly improved recurrence-free survival. This study investigates the real-world situation of 904 patients from 13 German skin cancer centers with an indication for adjuvant treatment since the approval of adjuvant ICI and TT. From adjusted log-binomial regression models, we estimated relative risks for associations between various influence factors and treatment decisions (adjuvant therapy yes/no, TT vs. ICI in BRAF mutant patients). Of these patients, 76.9% (95% CI 74-80) opted for a systemic adjuvant treatment. The probability of starting an adjuvant treatment was 26% lower in patients >65 years (RR 0.74, 95% CI 68-80). The most common reasons against adjuvant treatment given by patients were age (29.4%, 95% CI 24-38), and fear of adverse events (21.1%, 95% CI 16-28) and impaired quality of life (11.9%, 95% CI 7-16). Of all BRAF-mutated patients who opted for adjuvant treatment, 52.9% (95% CI 47-59) decided for ICI. Treatment decision for TT or ICI was barely associated with age, gender and tumor stage, but with comorbidities and affiliated center. Shortly after their approval, adjuvant treatments have been well accepted by physicians and patients. Age plays a decisive role in the decision for adjuvant treatment, while pre-existing autoimmune disease and regional differences influence the choice between TT or ICI.",
author = "Georg Lodde and Andrea Forschner and Jessica Hassel and Wulfken, {Lena M} and Friedegund Meier and Peter Mohr and Katharina K{\"a}hler and Bastian Schilling and Carmen Loquai and Carola Berking and Svea H{\"u}ning and Kerstin Schatton and Christoffer Gebhardt and Julia Eckardt and Ralf Gutzmer and Lydia Reinhardt and Valerie Glutsch and Ulrike Nikfarjam and Michael Erdmann and Andreas Stang and Bernd Kowall and Alexander Roesch and Selma Ugurel and Lisa Zimmer and Dirk Schadendorf and Elisabeth Livingstone",
year = "2021",
month = may,
day = "12",
doi = "10.3390/cancers13102319",
language = "English",
volume = "13",
journal = "CANCERS",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "10",

}

RIS

TY - JOUR

T1 - Factors Influencing the Adjuvant Therapy Decision: Results of a Real-World Multicenter Data Analysis of 904 Melanoma Patients

AU - Lodde, Georg

AU - Forschner, Andrea

AU - Hassel, Jessica

AU - Wulfken, Lena M

AU - Meier, Friedegund

AU - Mohr, Peter

AU - Kähler, Katharina

AU - Schilling, Bastian

AU - Loquai, Carmen

AU - Berking, Carola

AU - Hüning, Svea

AU - Schatton, Kerstin

AU - Gebhardt, Christoffer

AU - Eckardt, Julia

AU - Gutzmer, Ralf

AU - Reinhardt, Lydia

AU - Glutsch, Valerie

AU - Nikfarjam, Ulrike

AU - Erdmann, Michael

AU - Stang, Andreas

AU - Kowall, Bernd

AU - Roesch, Alexander

AU - Ugurel, Selma

AU - Zimmer, Lisa

AU - Schadendorf, Dirk

AU - Livingstone, Elisabeth

PY - 2021/5/12

Y1 - 2021/5/12

N2 - Adjuvant treatment of melanoma patients with immune-checkpoint inhibition (ICI) and targeted therapy (TT) significantly improved recurrence-free survival. This study investigates the real-world situation of 904 patients from 13 German skin cancer centers with an indication for adjuvant treatment since the approval of adjuvant ICI and TT. From adjusted log-binomial regression models, we estimated relative risks for associations between various influence factors and treatment decisions (adjuvant therapy yes/no, TT vs. ICI in BRAF mutant patients). Of these patients, 76.9% (95% CI 74-80) opted for a systemic adjuvant treatment. The probability of starting an adjuvant treatment was 26% lower in patients >65 years (RR 0.74, 95% CI 68-80). The most common reasons against adjuvant treatment given by patients were age (29.4%, 95% CI 24-38), and fear of adverse events (21.1%, 95% CI 16-28) and impaired quality of life (11.9%, 95% CI 7-16). Of all BRAF-mutated patients who opted for adjuvant treatment, 52.9% (95% CI 47-59) decided for ICI. Treatment decision for TT or ICI was barely associated with age, gender and tumor stage, but with comorbidities and affiliated center. Shortly after their approval, adjuvant treatments have been well accepted by physicians and patients. Age plays a decisive role in the decision for adjuvant treatment, while pre-existing autoimmune disease and regional differences influence the choice between TT or ICI.

AB - Adjuvant treatment of melanoma patients with immune-checkpoint inhibition (ICI) and targeted therapy (TT) significantly improved recurrence-free survival. This study investigates the real-world situation of 904 patients from 13 German skin cancer centers with an indication for adjuvant treatment since the approval of adjuvant ICI and TT. From adjusted log-binomial regression models, we estimated relative risks for associations between various influence factors and treatment decisions (adjuvant therapy yes/no, TT vs. ICI in BRAF mutant patients). Of these patients, 76.9% (95% CI 74-80) opted for a systemic adjuvant treatment. The probability of starting an adjuvant treatment was 26% lower in patients >65 years (RR 0.74, 95% CI 68-80). The most common reasons against adjuvant treatment given by patients were age (29.4%, 95% CI 24-38), and fear of adverse events (21.1%, 95% CI 16-28) and impaired quality of life (11.9%, 95% CI 7-16). Of all BRAF-mutated patients who opted for adjuvant treatment, 52.9% (95% CI 47-59) decided for ICI. Treatment decision for TT or ICI was barely associated with age, gender and tumor stage, but with comorbidities and affiliated center. Shortly after their approval, adjuvant treatments have been well accepted by physicians and patients. Age plays a decisive role in the decision for adjuvant treatment, while pre-existing autoimmune disease and regional differences influence the choice between TT or ICI.

U2 - 10.3390/cancers13102319

DO - 10.3390/cancers13102319

M3 - SCORING: Journal article

C2 - 34065995

VL - 13

JO - CANCERS

JF - CANCERS

SN - 2072-6694

IS - 10

M1 - 2319

ER -